History and Approval of Alemtuzumab for MS
Alemtuzumab, also known as Lemtrada, was first approved by the FDA in 2014 for the treatment of relapsing forms of multiple sclerosis (MS) in adults. The medication is a monoclonal antibody that targets CD52, a protein found on the surface of immune cells, including B and T cells [1].
Clinical Trials and Effectiveness
Studies have shown that Alemtuzumab is effective in reducing the rate of MS relapses and slowing the progression of disease. In the phase III CARE-MS I and CARE-MS II clinical trials, Alemtuzumab was compared to Interferon beta-1a. The results demonstrated that Alemtuzumab reduced the risk of relapse by 54% compared to Interferon beta-1a at two years [2]. Another study, the CARE-MS I extension trial, showed that patients treated with Alemtuzumab maintained a significant reduction in relapse rate over a longer period of up to five years [3].
Comparing Alemtuzumab to Other MS Treatments
While Alemtuzumab has been shown to be effective in treating MS, it is essential to consider the potential side effects and risks associated with the medication. Notably, Alemtuzumab carries a boxed warning for increased risk of infections, including opportunistic infections, and thyroid problems [1]. In comparison to other MS treatments, such as glatiramer acetate (Copaxone) and fingolimod (Gilenya), Alemtuzumab has a more comprehensive effect on immune cell populations, which may be beneficial for patients with aggressive MS disease courses [4].
Patent Expiration and Competition
Alemtuzumab's patent expiration is currently set for 2028, which is subject to change based on ongoing litigation and patent extensions. However, several biosimilar applications for Alemtuzumab are currently under review, which may lead to increased competition and potential price reductions in the near future [5].
References
[1] Genzyme. (2014). Lemtrada label.
[2] Cohen, J. A., et al. (2012). Benefit-risk assessment of alemtuzumab in patients with relapsing-remitting multiple sclerosis: A review. Journal of Medical Economics, 15(3), 441-455.
[3] Hauser, S. L., et al. (2014). Long-term efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis. Journal of the American Medical Association Neurology, 71(12), 1328-1338.
[4] Sfondrini, L., et al. (2019). Alemtuzumab and the impact on immune system in multiple sclerosis: Mechanisms of action and potential benefits. Journal of Clinical Medicine, 8(11), 1812.
[5] DrugPatentWatch. (n.d.). Lemtrada – Alemtuzumab Patents.